Proactive Investors - Run By Investors For Investors

Roth Capital Partners maintains Buy rating, $10 price target for cannabis company Hexo Corp

But Analyst Scott Fortune lowered his revenue and earnings forecasts for the Quebec-based cannabis company
hemp
Hexo should benefit from entering the US market (eight states) with its CBD products

Roth Capital Partners on Friday maintained its Buy rating and $10 price target for Hexo Corp (TSE:HEXO)(NYSEAMERICAN:HEXO), a day after the Canadian cannabis company reported fiscal third-quarter results.

But Analyst Scott Fortune lowered his revenue and earnings forecasts for Hexo, calling the company’s 3Q earnings “soft.”

Hexo, based in Gatineau, Quebec, reported net revenue of US$13 million, while Fortune expected US$15.7 million. The company also missed on adjusted gross profit — US$6.4 million versus an expected US$7.5 million.

READ: HEXO sees huge revenue jump in the third quarter but still misses estimates

As a result, Fortune wrote that he’s reducing his fiscal year 2019 revenue forecast by US$4.2 million to US$59.6 million, while maintaining his fiscal year 2020 forecast for US$63.8 million in revenue.

Despite lowering his revenue forecast, Fortune remains optimistic that Hexo “will gain market share in becoming a large tier” licensed producer.

“Although soft quarterly results, management reiterated FY20 guidance of $400M revenues and remains committed to break even in the FY20 timeframe,” he wrote.

Fortune noted that Hexo should benefit from entering the US market (eight states) with its CBD products and vape sales as well as increase annual production of cannabis up to 150,000 kilograms, “which justifies the doubling in revenue guidance in our opinion.”

CIBC downgrade

In related news, according to the Fly, CIBC Capital Markets analyst John Zamparo downgraded Hexo to Neutral from Outperformer, saying he doubts the company can achieve US$400 million in revenue in fiscal 2020.

He lowered his price target to C$8.50 from C$9.50 

Hexo’s stock recently traded down 4.2% to US$5.65 a share on the NYSE and fell 3.1% to C$7.57 in Toronto.

Within the last 12 months, ROTH has received compensation for investment-banking services from Hexo.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full HEXO profile View Profile

Related Articles

Dragonglass jars made by Spirulinex LLC, a partly owned subsidiary of GSRX Industries
05:43
Headquartered in Dorado, Puerto Rico, the medical cannabis company has fingers in many pies
cannabis plant
May 06 2019
The cannabis company invests in income-producing property and provides financing solutions and capital investment to service the blossoming cannabis industry
Sydney Harbour Bridge
January 23 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use